Сравнение

Buserelin vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

57982-77-1

396091-73-9

Молекулярная масса

1239.42 g/mol

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Buserelin	Pasireotid
Германия	Рецептурный	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Buserelin and Pasireotid?: Buserelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Pasireotid?: The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Pasireotid in Germany and the United States?: Германия: Buserelin — Рецептурный, Pasireotid — Рецептурный. США: Buserelin — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Pasireotid

Германия

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Buserelin and Pasireotid?

Buserelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Pasireotid?

The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Pasireotid in Germany and the United States?

Германия: Buserelin — Рецептурный, Pasireotid — Рецептурный. США: Buserelin — Не одобрено, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.